In a report released today, Yaron Werber from TD Cowen reiterated a Buy rating on Ascendis Pharma, with a price target of $227.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yaron Werber has given his Buy rating due to a combination of factors including the strong performance and growth potential of Ascendis Pharma’s products. Yorvipath has demonstrated impressive sales figures, significantly surpassing expectations and showing rapid adoption in the US market, which indicates a successful launch and promising future growth. The increase in patient start forms and the expansion of prescriber base further support the positive outlook for Yorvipath.
In addition, while Skytrofa faced some challenges due to currency headwinds, its potential for growth remains with the recent label expansion to adult growth hormone deficiency and upcoming trials. The anticipated positive data from the CNP/GH COACH Phase 2 trial and the upcoming MBX Phase 2 data are also expected to be significant catalysts for the stock. These factors collectively contribute to Werber’s optimistic view and the Buy rating for Ascendis Pharma.
In another report released on August 4, Morgan Stanley also maintained a Buy rating on the stock with a $250.00 price target.